ADC Review

Driven to improve patients’ lives, Byondis is an independent clinical-stage, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.

The company’s headquarters and state-of-the-art R&D and GMP manufacturing facilities are based in Nijmegen, the Netherlands. For more information, visit the company's website. Byondis started its biopharmaceutical activities in 2007. In 2012, the company became a new biopharmaceutical subsidiary and quickly built a promising pipeline of innovative research and development programs. After becoming an independent company in November 2019, the clinical-stage biopharmaceutical company rebranded itself as Byondis in April 2020. Byondis, a subsidiary of the holding company Byondis Holding B.V., operates under the leadership of its founder, Jacques Lemmens, PhD.

Pioneering a New Generation of ADCs and Monoclonal Antibody Therapies Byondis is working to bring meaningful therapeutic solutions to patients by breaking through the limitations of existing technologies and exploiting the weaknesses in cancer cells. Byondis’ pipeline includes clinical-stage, wholly owned, lead assets against validated cancer targets and a promising pre-clinical pipeline. The Company’s innovative drug development platform is based on enhanced tumor targeting selectivity, optimized linkers, broad diversity of targets, payloads & MoA including multi-specifics.

• BYON4228
  • is a novel monoclonal antibody (mAb) from Byondis’ next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors’ ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (
  NCT05737628
  • ) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (
  NCT06932952
  • ).
  ADC Drug Map Link
• BYON4413 is an ADC directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed in many hemato-oncological malignancies. Developed with Byondis ByonZine® and ByonShieLD® technologies, this investigational agent is currently in preclinical development. ADC Drug Map Link

Collaborative Research

To realize the full potential of our science, pipeline, and technology, Byondis is open to collaborations and partnerships among research institutions and biopharmaceutical companies. This includes licensing agreements, research partnerships, combination studies and commercialization agreements.

The ultimate goal:Making Hope Real for patients with a current unmet medical need. Click on the link to learn more about partnering with Byondis.

Key technologies

ByonZine®

Duocarmazine Linker-Drug Technology and cleavable DNA-damaging linker-drug. ADCs developed using this proprietary technology can effectively eliminate heterogeneous tumors via the unique target-mediated and bystander mechanisms of action and kills both dividing and non-dividing cancer cells with extremely low levels of free drug in circulation.

ByonNative®

A differentiated antibody conjugation platform which allows ADC generation via partially reduced native disulfide bonds. This is a proprietary process that removes unwanted non-conjugated and over-conjugated species and enables fast generation of ByonZine® ADCs with antibodies of interest.

ByonShieLD®

A site-specific antibody conjugation platform designed to create uniform ByonZine® ADCs via orthogonal cysteine activation and conjugation technology. Using a controlled method of connecting the linker-drug to the antibody, this technology shields the hydrophobic payload and creates ADCs with a superior therapeutic index and excellent manufacturability.

ByonFoLD®

A dual linker-drug antibody conjugation platform designed to create well defined two-in-one ADCs in which two different payloads are conjugated in a compatible fashion to a single antibody. This technology allows the creation of next-generation ADCs with synergistically operating dual payloads.

ByonBranch®

A branched linker technology. Branched linker technology allows the coupling of payloads to an antibody that results in ADCs with reduced hydrophobicity.